PTC Therapeutics to Host Conference Call to Discuss First Quarter 2015 Financial Results Print E-mail
PRNewsWire
Monday, 20 April 2015 07:02
SOUTH PLAINFIELD, N.J., April 20, 2015/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that the Company will host a webcast conference
Read more...
 
FDA Grants Fast Track Designation to Eiger Bio's Lonafarnib for Hepatitis Delta Virus (HDV) Infection Print E-mail
PRNewsWire
Monday, 20 April 2015 07:00
Eiger - Leader in HDV
Read more...
 
Intrexon Completes Acquisition of Okanagan Specialty Fruits Print E-mail
PRNewsWire
Monday, 20 April 2015 07:00
Intrexon Corporation logo Facebook
Read more...
 
Phase 1 Data from Spinal Muscular Atrophy Program to be Presented at the 2015 American Academy of Neurology Annual Meeting Print E-mail
PRNewsWire
Monday, 20 April 2015 07:00
WASHINGTON, April 20, 2015/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that Phase 1 clinical data from the company's joint development program
Read more...
 
DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM) Print E-mail
PRNewsWire
Monday, 20 April 2015 07:00
VANCOUVER, British Columbiaand MENLO PARK, Calif., April 20, 2015/PRNewswire/ -- DelMar Pharmaceuticals, Inc.(OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company
Read more...
 
Endobetix is a Finalist for the 2015 Red Herring Top 100 Europe Award Print E-mail
PRNewsWire
Monday, 20 April 2015 06:01
<!-- imageTagafter: <img src="http://content.prnewswire.com/designimages/mobile_twitter.png" alt="Endobetix is a Finalist for the 2015 Red Herring Top 100 Europe Award">and
Read more...
 
Important UCB presence at the 2015 American Academy of Neurology Meeting Print E-mail
PRNewsWire
Monday, 20 April 2015 06:00
BRUSSELS, April 20, 2015/PRNewswire/ -- UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research, is sponsoring a total of 24
Read more...
 
Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer Print E-mail
PRNewsWire
Monday, 20 April 2015 06:00
PETACH TIKVA, Israel, April 20, 2015/PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of
Read more...
 
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual Meeting Print E-mail
PRNewsWire
Monday, 20 April 2015 05:30
CALGARY, April 20, 2015/PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a series of poster presentations by the
Read more...
 
Curadev Announces Research Collaboration and Licensing Agreement to Develop Cancer Immunotherapeutic Print E-mail
PRNewsWire
Monday, 20 April 2015 05:30
Curadev Logo Facebook
Read more...
 
Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results Print E-mail
PRNewsWire
Monday, 20 April 2015 05:12
BEIJING, April 20, 2015/PRNewswire/ -- Sinovac Biotech Ltd. ( Nasdaq:SVA), a leading provider of biopharmaceutical products in China, today announced its
Read more...
 
NW Bio Featured In Presentations At the American Association for Cancer Research Annual Meeting Print E-mail
PRNewsWire
Monday, 20 April 2015 05:00
BETHESDA, Md., April 20, 2015/PRNewswire/ --  Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) ("NW Bio") , a biotechnology company developing DCVax ®personalized immune
Read more...
 
Immunocore Announces Positive Clinical Trial Data for Novel First-in-Class Immunotherapy at AACR Annual Meeting 2015 Print E-mail
PRNewsWire
Monday, 20 April 2015 01:00
OXFORD, England, April 20, 2015/PRNewswire/ -- IMCgp100 shows partial and
complete durable responses in  Phase I/IIa trial in patients with advanced melanoma
Read more...
 
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets Print E-mail
PRNewsWire
Sunday, 19 April 2015 14:15
CAMBRIDGE, Mass., April 19, 2015/PRNewswire/ -- Blueprint Medicines today announced new preclinical data demonstrating that its drug candidate BLU-285 has significant anti-tumor activity in
Read more...
 
Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloq™, its Novel Antibody Drug Conjugate Linker Technology and

Error. Page cannot be displayed. Please contact your service provider for more details. (13)

c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of the American Association for Cancer Research
Print E-mail
PRNewsWire
Saturday, 18 April 2015 15:32
Sorrento Therapeutics, Inc. Facebook
Read more...
 
<< Start < Prev 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 Next > End >>

Page 1584 of 2212
BMR:1